Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOTTINGHAM, KYLE GREGORY | 1 | 59.3% | +34.9% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.7% | +36.9% |
| YOO, SUN JAE | 1 | 71.0% | +0.3% |
| SHIM, DAVID M. | 1 | 57.8% | +55.9% |
| SAMSELL, RILLA MARIE | 1 | 72.0% | +15.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906650 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | SAMSELL, RILLA MARIE | 9d overdue |
| 18742035 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOTTINGHAM, KYLE GREGORY | — |
| 18542100 | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | SZPERKA, MICHAEL EDWARD | — |
| 18041490 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1621 | 1 |
| 1626 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18742035 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOTTINGHAM, KYLE GREGORY | — | §102§103§112DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18542100 | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | SZPERKA, MICHAEL EDWARD | 1641 | DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18500471 | Compositions and Methods for Treating Anemia | YOO, SUN JAE | 1621 | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18041490 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SHIM, DAVID M. | 1626 | §103 | Final Rejection | — | Pending | Feb 13, 2023 |
| 17906650 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | SAMSELL, RILLA MARIE | 1624 | §112 | Final Rejection | 9d overdue | Pending | Sep 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial